Prolonging Recurrence-Free Survival With Keytruda Does Not Come at the Price of Reduced Quality of Life for Patients with Melanoma
Source: curetoday.com, May 2021
Keytruda (pembrolizumab) does not significantly decrease health-related quality of life in patients with resected, high-risk stage 3 melanoma compared to placebo, according to data published in The Lancet.
“Given the need for safe and effective adjuvant therapies, the assessment of (health-related quality of life) is increasingly important, in part because of serious (side effects) associated with melanoma drug therapies,” the study authors wrote.
